Immunogenic cell death

EQS-News: DEFENCE THERAPEUTICS APPLAUDS UNITED STATES PRESIDENT BIDEN CANCER MOONSHOT INITIATIVE

Retrieved on: 
Monday, September 19, 2022
Control, Health, Engineering, E7, Cervical cancer, ADC, Catastrophic illness, Neoplasm, News, Company, Biotechnology, Melanoma, Moon, Therapy, Forward-looking statement, Survival, Cancer, Cancer Breakthroughs 2020, Breast cancer, EQS, CSE, Technology, Protein, Vaccine, Cell, Biomanufacturing, Rice University, RNA, DNA repair, DNA, Infection, Disease, Immunogenic cell death, Security (finance), Pharmaceutical industry, BC, Moonshot, Defense

Defence AccumTM is a biotechnology platform that is being extensively developed to enhance and increase the efficacy of any existing drugs against cancer, which is directly in line with the Cancer Moonshot program.

Key Points: 
  • Defence AccumTM is a biotechnology platform that is being extensively developed to enhance and increase the efficacy of any existing drugs against cancer, which is directly in line with the Cancer Moonshot program.
  • In addition to ADCs, Defence applied over the last 2 years, the AccumTM technology in the design of novel vaccines.
  • Defence Therapeutics is well positioned to prevent cancer and to enhance the efficacy of any drugs against cancer with its versatile technology: a solution looking for a cancer problem.
  • With all the cancer programs in development, Defence is in a strong position to truly make a difference and help to reduce the cancer death rate.

Candel Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for CAN-2409 in Glioma

Retrieved on: 
Thursday, September 15, 2022
Herpes simplex virus, CADL, FDA, MD, COMP, Brain, Food, Virus, European Medicines Agency, European Commission, Company, Population, Pancreatic cancer, Private Securities Litigation Reform Act, Therapy, Valaciclovir, Person, Neoplasm, Patient, Clinical trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, Disease, CEO, Technology, Nasdaq, Doctor of Philosophy, Immunogenic cell death, HSV, Lung, Tumor microenvironment, Committee, Large-cell lung carcinoma, Prostate cancer, Royal commission, SEC, Union, Mortality, Content discovery platform, Marketing, GLOBE, EMA, Pharmaceutical industry, Vaccine, Fellow of the Academy of Medical Sciences, EU, Candel, Glioma

The orphan drug designation follows the U.S. Food and Drug Administration (FDA) fast track designation, which was granted in June 2021, for CAN-2409 in combination with valacyclovir following standard of care treatment in newly diagnosed high-grade glioma.

Key Points: 
  • The orphan drug designation follows the U.S. Food and Drug Administration (FDA) fast track designation, which was granted in June 2021, for CAN-2409 in combination with valacyclovir following standard of care treatment in newly diagnosed high-grade glioma.
  • Paul Peter Tak, MD, PhD, FMedSci, President and CEO of Candel, said, "Glioma, while mercifully rare, is a devastating disease with significant morbidity and mortality.
  • The EMA's orphan drug designation recognizes the high unmet need and the potential of CAN-2409 in this patient population.
  • Orphan drug designation in the European Union (EU) is granted by the European Commission based on a positive opinion issued by the EMA COMP.

Promontory Therapeutics Appoints Two Experienced Executives to Its Core Management Team

Retrieved on: 
Tuesday, September 13, 2022
Merck Group, CMC, Trial of the century, LLC, Promontory, Fellow, Shea, NEW, Prostate, AMAG Pharmaceuticals, Damage-associated molecular pattern, Thymic carcinoma, Ferris, Industry, Therapy, Merck Serono, ICD, NCI, Control, ARIAD Pharmaceuticals, Dartmouth College, Doctor of Philosophy, Orphan drug, Drug development, Albemarle Corporation, Immunogenic cell death, Kate, Lung, Tumor microenvironment, Research, B cell, Texas A&M University, Pharmaceutical industry, Science, Chemistry, IQVIA, Organic chemistry

NEW YORK, Sept. 13, 2022 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, today announced the appointments of Helene Shea, PhD, as Vice President of Chemistry, Manufacturing and Controls (CMC), and Kate Hogg Call as Vice President of Clinical Operations.

Key Points: 
  • "We could not be more pleased to add Helene and Kate's collective strengths to our team."
  • "Promontory is at a critical inflection point where clinical trials are expanding globally, and drug supply must scale accordingly.
  • Promontory Therapeutics Inc. is a privately held, clinical stage pharmaceutical company focused on small molecule immunotherapy.
  • To learn more about Promontory Therapeutics, visit the company's website here .

Candel Therapeutics Announces Two Executive Leadership Appointments

Retrieved on: 
Wednesday, September 7, 2022
CEO, Technology, Virus, GSK, CADL, Infection, Internal medicine, LTD, Content discovery platform, Certified Public Accountant, GLOBE, Company, Smallpox, Patient, Deloitte, Cancer, University of Washington Department of Bioengineering, Seattle Cancer Care Alliance, Board, Genzyme, Duke University, SEC, CFO, GlaxoSmithKline, Nasdaq, MS, Treasurer, New England Baptist Hospital, Therapy, Immunogenic cell death, Disease, Acer, Commonwealth, HSV, Faculty, HIV, ViiV Healthcare, Fred Hutchinson Cancer Research Center, Private Securities Litigation Reform Act, CMO, University, IPO, HIV/AIDS, Epidemiology, Family, Pharmaceutical industry, Management, Vaccine, Fellow of the Academy of Medical Sciences, Akebia, Candel, MD, Doctor of Philosophy, Boston College

Mr. Amello and Dr. Nichols together bring over five decades of biopharmaceutical experience to Candel.

Key Points: 
  • Mr. Amello and Dr. Nichols together bring over five decades of biopharmaceutical experience to Candel.
  • He was instrumental in shaping the Company as we executed our IPO in 2021 and has continued to provide valuable strategic guidance to Candel.
  • On behalf of the board, the leadership team and all of the Candel employees, we wish him well.
  • Mr. Amello comes to Candel from Saniona AB, a rare disease biotech company where he served as CFO.

Candel Therapeutics Upcoming Investor Conference Participation

Retrieved on: 
Tuesday, September 6, 2022
Technology, Cancer, Immunogenic cell death, News, Virus, HSV, SEC, Content discovery platform, Company, Form, Investor, Webcast, Private Securities Litigation Reform Act, Patient, Vaccine, Candel

A live webcast of the H.C. Wainwright company presentation is available here and can be accessed by visiting the Investors section of Candel Therapeutics website at www.ir.candeltx.com and selectingEvents and Presentationsunder the News & Events tab.

Key Points: 
  • A live webcast of the H.C. Wainwright company presentation is available here and can be accessed by visiting the Investors section of Candel Therapeutics website at www.ir.candeltx.com and selectingEvents and Presentationsunder the News & Events tab.
  • A replay of the webcast will be archived for up to 90 days following the presentation date.
  • CAN-2409 is the lead product candidatefrom the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform.
  • The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 4, 2022
Goal, Melanoma, Securities Exchange Act of 1934, NASDAQ, Bristol Myers Squibb, Herpes simplex virus, PFS, Breast cancer, CD40L, Marketing, RP3, CRC, RP1, Protein, RP2, Safety, FDA, Cancer, Antigen, Immunogenic cell death, NSCLC, GLOBE, U.S. Securities and Exchange Commission, Colorectal cancer, Sale, Coronavirus, Large-cell lung carcinoma, MOA, Neck, GI, SCCHN, RPX, Neoplasm, Lung cancer, Head, HCC, CSCC, Patient, Review, Hepatocellular carcinoma, ORR, Uveal melanoma, Clinical trial, Securities Act of 1933, Drug Quality and Security Act, Skin, Security (finance), D, CR, MSI, Lymph, Company, Progression-free survival, Program, Tumor microenvironment, Investment, Forward-looking statement, Research, Toxicity, TME, Squamous cell carcinoma, Pharmaceutical industry, Medical imaging, Vaccine, Nivolumab, Sanofi, Regeneron Pharmaceuticals

WOBURN, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2022 and provided a business update.

Key Points: 
  • Our ambition to establish a major skin cancer franchise, built off of our lead RP1 program, is progressing to plan.
  • R&D Expenses: Research and development expenses were$29.5 millionfor the first quarter ended June 30, 2022, as compared to$18.6 millionfor the first quarter ended June 30, 2021.
  • S,G&A Expenses: Selling, general and administrative expenses were$11.4 millionfor the first quarter endedJune 30, 2022, as compared to$8.8 millionfor the first quarter endedJune 30, 2021.
  • Our actual results could differ materially from the results described in or implied by such forward-looking statements.

Replimune to Present at Two Upcoming Investor Conferences

Retrieved on: 
Monday, August 1, 2022
MOA, NASDAQ, TME, RPX, Immunogenic cell death, Neoplasm, GLOBE, Antigen, Safety, Tumor microenvironment, Pharmaceutical industry, Vaccine

Replimunes proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response.

Key Points: 
  • Replimunes proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response.
  • The RPx platform has a unique dual local and systemic mechanism of action (MOA) consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment (TME) to ignite a strong and durable systemic response.
  • This MOA is expected to be synergistic with most established and experimental cancer treatment modalities, and, with an attractive safety profile the RPx platform has the versatility to be developed alone or combined with a variety of other treatment options.
  • For more information, please visit www.replimune.com .

Candel Therapeutics Appoints Three New Members to its Board of Directors

Retrieved on: 
Monday, August 1, 2022
CFO, KPMG, CADL, Perrigo, Bausch Health, Chief executive officer, Company, Public, Transaction, Immunogenic cell death, Acquisition, Doctor of Philosophy, Â, Research, Accounting, American Society for Biochemistry and Molecular Biology, Cancer, Virology, Smith & Nephew, Actavis, Growth, HIV, Society, SARS, IPO, GLOBE, Board, CEO, SEC, Harvard Business School, Institute, Novartis, Organization, Bausch & Lomb, Cardinal Health, Science, Biochemistry, Loyola Marymount University, Molecular biology, Vaccine, Network for Excellence in Health Innovation, HSV, Private Securities Litigation Reform Act, National academy, Therapy, BS, Leadership, Senior, Patient, Certified Public Accountant, Market for corporate control, Eko, Management, Pharmaceutical industry, Fellow of the Academy of Medical Sciences, Chikungunya, Sanofi, Candel, MD

These new members replace current Board members: Alan E. Smith, PhD, Shaan Ghandi, MD, D.Phil, and Udi Meirav, PhD, maintaining Candels nine-seat board.

Key Points: 
  • These new members replace current Board members: Alan E. Smith, PhD, Shaan Ghandi, MD, D.Phil, and Udi Meirav, PhD, maintaining Candels nine-seat board.
  • We are pleased to welcome Renee, Gary, and Joseph, preeminent leaders in their respective fields, as new directors to the Candel Board, said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer (CEO) at Candel.
  • Dr. Nabel co-founded ModeX Therapeutics and held the position of President and CEO before its acquisition by OPKO in May 2022.
  • In July 2022, he stepped down as chair of Bausch + Lombs Board and will remain CEO until his successor is appointed.

Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)

Retrieved on: 
Tuesday, June 28, 2022
Merck Serono, BCMA, Patient, ADC, Control, Biotechnology, Modality, Pembrolizumab, Research, Merck Group, GLOBE, BMS, Cancer, COVID-19, Growth, TSE, Immunogenic cell death, Sutro, Goal, Advertising, U.S. Securities and Exchange Commission, Forward-looking statement, Metastasis, NSCLC, Immune system, Merck, Partnership, IADC, Security (finance), Bristol Myers Squibb, Private Securities Litigation Reform Act, Neoplasm, Environment, Antibody, Survival, Lymphoid leukemia, B cell, JD, NASDAQ, Tumor microenvironment, Multiple myeloma, Cytotoxicity, Large-cell lung carcinoma, Twitter, Biology, Knowledge, STRO, Protein engineering, Medical imaging, Vaccine, Risk management, Pharmaceutical industry, Astellas Pharma

TOKYO and SOUTH SAN FRANCISCO, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Sutro Biopharma, Inc. (NASDAQ: STRO, CEO: William J. Newell, JD, “Sutro”) today announced a worldwide, strategic collaboration and licensing agreement focused on the discovery and development of novel immunostimulatory antibody-drug conjugates (iADCs). The collaboration leverages the unique cancer-fighting potential of iADCs as a novel modality, enabled by Sutro’s ability to engineer complex conjugated antibodies, and Astellas’ global oncology R&D expertise.

Key Points: 
  • The collaboration leverages the unique cancer-fighting potential of iADCs as a novel modality, enabled by Sutros ability to engineer complex conjugated antibodies, and Astellas global oncology R&D expertise.
  • Sutro is a leading company in the area of iADCs, a new modality, and has its own original iADC technologies.
  • The strategic partnership with Sutro will help us expand our pipeline and widen the choice of cancer immunotherapies.
  • Sutro Biopharma, Inc. (Sutro), headquartered in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs).

Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)

Retrieved on: 
Tuesday, June 28, 2022
Merck Serono, BCMA, Patient, ADC, Control, Biotechnology, Modality, Pembrolizumab, Research, Merck Group, BMS, Cancer, COVID-19, Growth, TSE, Immunogenic cell death, Sutro, Goal, Advertising, U.S. Securities and Exchange Commission, Multimedia, Folate receptor, Forward-looking statement, Metastasis, NSCLC, Immune system, Fast Track, Sutro Biopharma, Merck, Partnership, IADC, Security (finance), Environment, Bristol Myers Squibb, Private Securities Litigation Reform Act, Neoplasm, Technology, Antibody, Lymphoid leukemia, Survival, B cell, JD, Risk, NASDAQ, Tumor microenvironment, Multiple myeloma, Cytotoxicity, Large-cell lung carcinoma, Biology, Knowledge, STRO, Protein engineering, Medical imaging, Vaccine, Risk management, Pharmaceutical industry, Astellas Pharma

TOKYO and SOUTH SAN FRANCISCO, Calif., June 27, 2022 /PRNewswire/ --  Astellas Pharma Inc. (TSE: 4503), (President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Sutro Biopharma, Inc. (NASDAQ: STRO), (CEO: William J. Newell, JD, "Sutro") today announced a worldwide, strategic collaboration and licensing agreement focused on the discovery and development of novel immunostimulatory antibody-drug conjugates (iADCs). The collaboration leverages the unique cancer-fighting potential of iADCs as a novel modality, enabled by Sutro's ability to engineer complex conjugated antibodies, and Astellas' global oncology R&D expertise.

Key Points: 
  • The collaboration leverages the unique cancer-fighting potential of iADCs as a novel modality, enabled by Sutro's ability to engineer complex conjugated antibodies, and Astellas' global oncology R&D expertise.
  • Sutro is a leading company in the area of iADCs, a new modality, and has its own original iADC technologies.
  • The strategic partnership with Sutro will help us expand our pipeline and widen the choice of cancer immunotherapies."
  • Sutro Biopharma, Inc. (Sutro), headquartered in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs).